No announcement yet.

Just a peek into insurance/marketing of Ocrevus

  • Filter
  • Time
  • Show
Clear All
new posts

  • Just a peek into insurance/marketing of Ocrevus

    From May 2017:
    " Ocrevus (ocrelizumab) for primary progressive multiple sclerosis (PPMS) and relapsing MS (RMS), approved March 29: The infusible from Genentech USA, Inc., a Roche Group company, is the only treatment the FDA has approved for PPMS, which is diagnosed in about 15% of people with MS, says Kunze. “It will likely be approved for primary progressive MS without much pushback from plans,” she says. People with PPMS “technically shouldn’t be getting treated because nothing is approved for that indication. We assume this is an untreated population, but we know current therapies are being used off label,…but we don’t know to what extent,” since ICD-9 and ICD-10 codes just indicate a diagnosis of MS.

    However, Kunze says, Ocrevus’ use in RMS will be “an interesting battle” in that it’s “priced pretty competitively to” other self-injected therapies that treat the condition: $65,000 annually.

    from :